Dnurse Submits IPO Prospectus: China's Only AI-Powered Glucose Management Platform with FDA-Cleared insulinK™ and Dnurse App, Positioned as a Domestic Counterpart to WellDoc

Recently, Tanghushi has just completed its insulin pen injection dose collection deviceinsulinK^TM...and the U.S. FDA Class I registration for the accompanying English version of the Dnurse app. In light of this, VCBeat interviewed Li Chengzhi, founder of Tang Hushi (Diabetes Nurse).

According to Li Chengzhi,insulinK^TMIt is the world’s first automatic insulin pen injection dose collection device, released by Dnurse in September last year. This compact accessory can be attached to an insulin pen. Leveraging high-precision digital microphones, audio processing technology, and specialized noise reduction algorithms, it automatically records the dosage of each insulin injection. The data is then transmitted via Bluetooth to the Dnurse APP on a smartphone, which automatically uploads the data logs to a cloud server, enabling doctors and family members to monitor the information and provide timely interventions.

After accumulating extensive blood glucose data, along with dietary, exercise, and medication information, Tang Hushi has established a substantial out-of-hospital foundational database for diabetes management.Its Intelligent Decision Support System (IDSS) for diabetes is currently the only diabetes management tool in China centered on intelligent decision-making.

Dnurse APP

The system provides real-time, personalized, and professional recommendations on lifestyle behaviors for patients with diabetes, guiding them toward more beneficial behavioral pathways to improve patient adherence and enhance self-management capabilities.

In fact, effective diabetes management is clearly inadequate without continuous medication data. Medication adherence among patients taking oral hypoglycemic agents is significantly lower than that among insulin users. Meanwhile, inter-individual variability in the pharmacokinetics of insulin is much smaller compared to oral medications, and there is a direct, strong correlation between insulin dosage and blood glucose levels.

Therefore, accurately recording each insulin injection dose and correlating it with diet, physical activity, and blood glucose levels during the corresponding time periods in a data log holds significant clinical importance.

Not only does it assist physicians in rationally adjusting treatment plans, but the multidimensional data on medications and blood glucose also provide a relatively complete closed-loop safeguard for the precision of intelligent decision-making. More importantly, it helps to prevent life-threatening hypoglycemia caused by insulin overdose as much as possible. This was developed by Tang Hushi.insulinK^TMreasons for.

insulinK^TM 

Once a patient is confirmed to require insulin therapy, the physician will formulate an initial dosage regimen based on the patient’s individual condition. Subsequently, nurses or third-party health management agencies affiliated with insulin manufacturers will conduct follow-up visits to continuously adjust the injection dosage until optimal therapeutic outcomes are achieved.

It is well known that human blood glucose levels are directly related to dietary intake (primarily carbohydrate consumption) and physical activity; ignoring these factors makes it impossible to provide an appropriate insulin dosing regimen.

In fact, prior to the emergence of mobile health companies such as Tang Hushi, it was difficult for physicians and pharmaceutical companies to ascertain patients’ real-life conditions after they left the hospital.

Tang Hushi’s business model leverages a diabetes management tool that combines “intelligent device data collection with human-AI collaborative decision support” to provide patients with services that improve adherence and enhance self-management capabilities, while offering pharmaceutical and medical supply chain enterprises a low-cost, high-efficiency solution to boost sales of medications and consumables and reduce the complication-related payout ratios for commercial health insurers.

Li Chengzhi stated:“From a business perspective, insulin companies are the most in need ofinsulinK^TMof”. ThroughinsulinK^TM...and the APP can effectively manage patient dropout rates remotely, ensure patients administer the full prescribed dose of insulin as directed, and maintain stable blood glucose control corresponding to insulin dosages, among other benefits.

This technology not only significantly boosts sales among existing insulin users but also provides direct benefits in helping patients maintain stable blood glucose control and reduce the incidence of complications.Certainly, it also holds profound significance for reducing the heavy socioeconomic burden caused by severe complications.

According to VCBeat, the three major insulin brands are currently all owned by European and American companies with global business operations.Although Li Chengzhi did not explicitly confirm,Tang Hushi vs.insulinK^TMThe intention to register the app with the FDA should be stated here.

Furthermore, in addition to its business collaborations with diabetes internet management companies in Europe and Israel, Tang Hushi has established key partnerships in India with BeatO, a well-known diabetes management company, and Cooey, a chronic disease management company.

Thus, the commercial purpose behind the FDA registration of the Tang Hushi product is self-evident.